Market News AIOpen the app

Tempest Therapeutics shared its third quarter 2026 results, showing progress in its CAR-T treatments and gaining up to $50 million.

ResultsRead the original at globenewswire.com
Neutral

Tempest licensed Senlang's CD7 platform and gained access to up to $50 million, but ended the quarter with $0.9 million in cash. The pipeline and funding steps are balanced by the small cash balance and the lack of detailed trial results, so the report does not point clearly one way.

TPST · Tempest Therapeutics

AI read · Neutral

The AI's read

The licensed platform gives Tempest another treatment approach to develop, and access to up to $50 million could support that work. The company also completed a private placement, but did not report its size or detailed trial results. Its $0.9 million cash balance is a serious constraint, so the pipeline and funding news do not point clearly in one direction.

Get alerts for TPST

Follow Tempest Therapeutics (TPST) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TPST
Free on the App Store and Google Play, or on the web.